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Abstract: There are no existing affordable diagnostics for sensitive, rapid, and on-site detection of
pathogens in milk. To this end, an on-site colorimetric-based sustainable assay has been developed
and optimized using an L16 (54) Taguchi design to obtain results in hours without PCR amplification.
To determine the level of Escherichia coli (E. coli) contamination, after induction with 150 µL
of breast milk, the B-Per bacterial protein extraction kit was added to a solution containing
an alginate-based microcapsule assay. Within this 3 mm spherical novel sensor design, X-Gal
(5-Bromo-4-Chloro-3-Indolyl β-d-Galactopyranoside) was entrapped at a concentration of 2 mg/mL.
The outward diffusing X-Gal was cleaved by β-galactosidase from E. coli and dimerized in the
solution to yield a blue color after incubation at 40 ◦C. Color intensity was correlated with the level
of E. coli contamination using a categorical scale. After an 8 h incubation period, a continuous
imaging scale based on intensity normalization was used to determine a binary lower limit of
detection (LOD), which corresponded to 102 colony forming unit per mL (CFU/mL) and above.
The cost of the overall assay was estimated to be $0.81 per sample, well under the $3 benchmark for
state-of-the-art immune-based test kits for pathogen detection in biofluids. Considering the reported
binary LOD cutoff of 102 CFU/mL and above, this proposed hydrogel-based assay is suited to meet
global requirements for screening breast milk or milk for pathogenic organisms of 104 CFU/mL, with a
percentage of false positives to be determined in future efforts.
Keywords: bioassay; breast milk; alginate; optimization; sustainable; E. coli; pathogen detection;
Taguchi method; biosensor
1. Introduction
Breast milk is widely considered to be the gold standard for infant nutrition, offering essential
nutrients and antibodies that enhance an infant’s health outcomes [1,2]. Breastfeeding lowers the risk
of infectious disease during infancy and reduces the likelihood of chronic conditions, such as asthma,
during early childhood [3]. Breastfeeding has also been linked to improved cognitive development [4]
and reduced infant mortality worldwide [5]. However, mothers infected with HIV or other bloodborne
diseases are advised not to breastfeed [6]. Children with metabolic conditions preventing proper
digestion of breast milk or an inability to latch onto their mother’s breast to feed are also unable to
obtain sustenance via breast milk [7]. In addition, pumping inaccessibility due to cultural factors also
constitutes a barrier to breastfeeding [8]. These obstacles have led to a global emergence of breast
milk banks that increase the accessibility of uncontaminated breast milk for many mothers and their
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infants [9]. Stringent controls have been put in place at these milk banks to ensure the safety of milk
pumped and donated to these milk banks [10]. After testing donors for bloodborne diseases, donated
milk is pasteurized to reduce the count of harmful bacteria and tested by culturing to confirm the safety
of the milk [10]. Measures put in place to ensure the safety of donated milk may not always ensure
that levels of bacterial contaminants are within safe levels [9], as equipment, processes, and personnel
can fail [10]. However, culturing bacteria for quality control is an expensive (ranging from $35 to $81
to process approximately 100–200 ounces plus labor cost [11]) and time-consuming process [10] that is
not strain-specific, resulting in a high incidence of false negatives. In addition, culture-based safety
criteria are not standardized globally, leading to potential variation in bacterial content from different
milk banks [10]. Highlighted in Table 1 are diagnostic technologies for milk and food, their varying
purposes, detection methods, prices, applications, and times required to obtain results. Happy Vitals
test kits and Milkscreen strips are commercially available, while bioassays for quality assurance of
dairy products, food bioassays, electrochemical DNA-based bioassays, poly(methyl methacrylate)
(PMMA) “Lab-on-a-chips” for human breast milk defatting, integrated rotary microfluidic systems,
and wireless antibody-free biosensors are still in research stage.
Table 1. Currnt diagnostic technologies for contaminant detection in biofluids.
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Papers or bioactive paper assays for bacterial detection in dairy milk and orange juice exist in
a simple kit that would allow untrained personnel to carry out sensitive, multiplexed detection of
Escherichia coli (E. coli) in food samples [24,25]. These paper-based assays utilize sol-gel-derived silica
inks placed by an ink-jet printing technique to produce colorimetric results, which can be judged
by the human eye or a combination of a digital camera and image analysis software. The bioactive
paper assay is based on intracellular β-galactosidase or β-glucuronidase (GUS) hydrolysis of X-Gal
(5-Bromo-4-Chloro-3-Indolyl β-d-Galactopyranoside). For E. coli in breast milk, the lower limit of
detection (LOD) was reported to be 105 colony forming unit per mL (CFU/mL) [26] for a two hour
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assay, at a cost of $0.34. However, the use of a paper-based assay that implements a lateral flow method
for bacterial lysates to interact with an entrapped substrate may also result in contaminant entrapment,
suggesting that further improvements are necessary [9].
Motivated by these observations, a bioactive assay for detection of pathogens that is sensitive
(capable of detecting less than 105 E. coli), rapid (with assay development times between two and eight
hours), portable (no amplification needed and associated capital costs), environmentally friendly (no
solvents and biodegradable), low-cost and requiring minimal training was developed. In order to
circumvent contaminant entrapment, a simple assay design based on radial diffusion of an entrapped
X-Gal substrate from an alginate microcapsule was proposed. The mass transfer component of the
assay was comprised of a cross-linked alginate membrane with an established molecular weight cutoff
(MWCO) of 70 kDa [27]. Alginate, composed of (1,4)-linked β-d-mannuronic and (1,3)-α-l-guluronic
acid residues, is a widely used biomaterial in tissue engineering and regenerative medicine [28].
The kinetic component of the assay was based on the reaction of β-galactosidase, which hydrolyzes
X-Gal (MW: 408.629 Da), releasing a substituted indole (5-bromo-4-chloro-3-hydroxyindole) that
spontaneously dimerized into 5,5′-dibromo-4,4′-dichloro-indigo to give an intensely blue product [29].
The final assay design was achieved by dynamic optimization using Taguchi designs.
2. Materials and Methods
2.1. Materials
E. coli strain SCU-104, a naturally occurring commensal E. coli isolated from an SCU student under
an institutional review board-approved (IRB-approved) protocol, was used for all testing described here.
SCU-104 is capable of metabolizing lactose and shows regulatory behavior with regard to the lac operon
that conforms to classic models. Luria Bertani broth (LB, cat# L3152-1KG, lot# SLBS0893V) powder,
N,N-Dimethylformamide (DMF, cat# D4551-250ML, lot# SHBH9171), medium-viscosity alginic acid
(cat# A2033, lot# 108K1228), andβ-galactosidase (Aspergillus orizae; cat# 65160-125KU, lot# SLBB6762V,
activity: 10.3 U/mg) were purchased from Sigma-Aldrich (St. Louis, MI, USA). The B-PER Direct Bacterial
Protein Extraction Kit (Waltham, MA) and X-Gal (5-Bromo-4-Chloro-3-Indolyl β-d-Galactopyranoside,
cat# B1690, lot# 1899771) were procured from Thermo Fisher Scientific (Waltham, MA, USA). All other
reagent grade chemicals were provided by the Bioengineering Department at Santa Clara University,
Santa Clara, California, USA).
2.2. Methods
2.2.1. Cell Preparation
E. coli strain SCU-104 was cultured in 2 mL of 2.5% (w/v) autoclaved LB broth. Optical density (OD:
600nm) was monitored hourly using a Genesis 10S UV-Vis spectrophotometer (Thermo Fisher Scientific,
Waltham, MA, USA) [30]. During assay development, when the medium reached an absorbance
of 0.2–0.4 (after approximately 6 h), breast milk was added to induce expression of the lac operon.
Cultures were then incubated overnight in an incubator shaker at 37 ◦C and 220 rpm. Subsequently,
log-phase cells (approximately 108 cells/mL) were harvested by centrifugation at 3000 rpm for 5 min.
The bacterial cell pellet was resuspended in 200 µL of 50 mM sterile sodium phosphate buffer (pH = 7.4).
A range of bacterial cell concentrations (3.16 × 105–1.00 × 107 CFU/mL) was prepared in order to
construct a scaled detection ladder for optimization experiments. For the lower LOD determination,
a range of 0–1.00 × 108 (CFU/mL) was used post induction. Two separate batches of bacteria but a single
batch of breast milk were used for the above-stated optimization and LOD determination experiments.
2.2.2. Enzyme Extraction
E. coli cells were lysed in order to access intracellular β-galactosidase protein according to the
B-PER extraction protocol [31]. Two hundred microliters of B-PER protein extraction solution (1–5%
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(v/v) lysozyme, 1–5% (v/v) DNAase, and 90–98% (v/v) B-PER) was added to E. coli. The solutions
were then vortexed and incubated at 37 ◦C for lysing times ranging from 10 to 25 min. A primary
positive control for enzyme induction comprised of 1 mg of X-Gal powder was added to the lysed
solution corresponding to the highest concentration in the bacterial ladder (1.00 × 107 CFU/mL),




Shown in Figure 1 are the microcapsule fabrication steps. A 3% (w/v) solution of alginate was
prepared using 0.9% (w/v) NaCl as a solvent and autoclaved. X-Gal volumes ranging from 25 to 100 µL
aliquoted from a stock solution of 20 mg X-Gal/DMF (1:19, v/v) were dissolved in 1 mL of alginate and
stirred for 4 h. Alginate gel assay fabrication was based on the principle of ionotropic gelation [27].
The biopolymer mixture was extruded at 1 mL/min through a standard 304 SS 18 gauge needle (Rame
Hart, NJ, USA) into a 1.5% CaCl2 solution for cross-linking. After 30 min, the resultant hydrogel
capsules were washed three times with 0.9% NaCl to stop cross-linking.
Assay Indicators
Post induction with breast milk, the lysed solutions of the bacterial dilution ladder were used to
simulate contaminated samples at the milk bank, after which a single microcapsule containing the
X-Gal substrate was added to the mixture. As X-Gal diffused out of the microcapsule, it was cleaved
by β-galactosidase, which was the basis of the colorimetric assay.
Since the assay membrane is impermeable to β-galactosidase, capsule burst as a result of oncotic
pressure was a binary indicator of protein expression. Due to the discrete nature of the variable
(burst/no burst), the sample size needed to determine statistical power was too large. Hence, capsule
burst was not used in this study as an indicator of contamination.
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Figure 1. Schematic of the hydrogel capsule fabrication process.
2.2.4. Monitoring Biomolecular Activity on the Assay
Controls
Empty microcapsules and those containing 100 µL by volume of the X-Gal substrate (equivalent
to a concentration of 2 mg/mL) were used as negative and positive controls for catalytic activity. In past
studies, empty microcapsules turned blue, if alginates were not sterilized, resulting in a false positive
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outcome as a result of yeast contamination [9]. The controls were incubated in commercially available
free β-galactosidase at a concentration of 10 mg/mL (activity: 10.3 U/mg) in order to ensure effective
substrate encapsulation.
Categorical Scale for Optimization Runs
Biomolecular activity on the assay was monitored hourly or bi-hourly time intervals, before
the optimum times for observation and data collection were executed. During optimization and
confirmation experiments, the intensity (I) of the blue color was observed by the human eye referencing
the scale presented in Figure 2, derived by assigning arbitrary values to the range of blue intensities
produced in experiments.
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2.2.5. Assay Optimization
In order to determine which variables had the greatest impact on the assay performance, an L16
Taguchi orthogonal array experiment was conducted with a “larger-the-better” optimization goal [32].
The experimental design matrix was conducted according to the layout in Table 2. This design entailed
a four-level, five-variable array of different combinations of the following variables: volume of breast
milk used for induction (BreastMilk Volume), lysis incubation time (Lysing Time), volume of X-gal
substrate encapsulated in each capsule (X-Gal Volume, 100 µL = 2 mg/mL), concentration of E. coli
cells (Contamination Level), and assay temperature (Temperature). Shown in Table 2 are the uncoded
levels of the variables. The 16 combinations of five variables denoted as runs A–P were prepared for
deposition on alginate capsules. Each run was conducted once, while subsequent confirmation runs
were conducted in triplicate.
The optimized level of parameters was determined by the difference (D), rank (R), signal-to-noise
ratios (S/N), and gain (G) using the larger-the-better-optimization, which were given as following.







where X = S/N or X = I and I is the categorical intensity ranking based on Figure 2.
Rank, R, was given by:









where i, j, and l correspond to the level, factor, run#, respectively, and L is the total number of levels.
The theoretical signal-to-noise ratio (dB) for the lth experiment (S/N)l was defined by n, the total
number of replicates per experiment, and the observed color intensity for the mth trial of the lth
experiment Ymj,. Since runs were not replicated (m = n = 1), the equation for the average S/N was
simplified as:
(S/N)l = −10 log10
 1Y2l
. (4)
The gain was defined as the sum of weighted ranks (wj) for a given difference expressed in terms




w j(S/N)i j. (5)
If a solution to the optimization problem resided in the experimental space, the optimal level of
variables was a compromise between the highest gain and the acceptable response D expressed in
terms of intensity (I).
2.2.6. Assay Development Material Cost
The material cost for the individual assay was calculated by adding the amount of alginate, X-Gal,
and lysing solution components.
2.2.7. Statistical Analysis
Statistical analysis was conducted using MATLAB v2019a (Mathworks, Natick, MA, USA).
A one-sided student t-test for independent means at a significance level of 5% (α = 0.05) was conducted
on feature-extracted color intensity measurements.
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Table 2. Layout of experimental runs for assay optimization using the Taguchi L16 (54) design.
Runs BreastMilk Volume Lysing Time X-Gal Volume Contamination Level Temperature
A 0 µL 10 min 25 µL 3.16e7 23 ◦C
B 0 µL 15 min 50 µL 1.00e7 37 ◦C
C 0 µL 20 min 75 µL 1.00e6 40 ◦C
D 0 µL 25 min 100 µL 3.16e5 45 ◦C
E 50 µL 10 min 50 µL 1.00e6 45 ◦C
F 50 µL 15 min 25 µL 3.16e5 40 ◦C
G 50 µL 20 min 100 µL 3.16e7 37 ◦C
H 50 µL 25 min 75 µL 1.00e7 23 ◦C
I 100 µL 10 min 75 µL 3.16e5 37 ◦C
J 100 µL 15 min 100 µL 1.00e6 23 ◦C
K 100 µL 20 min 25 µL 1.00e7 45 ◦C
L 100 µL 25 min 50 µL 3.16e7 40 ◦C
M 150 µL 10 min 100 µL 1.00e7 40 ◦C
N 150 µL 15 min 75 µL 3.16e7 45 ◦C
O 150 µL 20 min 50 µL 3.16e5 23 ◦C
P 150 µL 25 min 25 µL 1.00e6 37 ◦C
3. Results
3.1. Controls
Shown in Figure 4a,b are the controls used for each experiment. The empty microcapsules (negative
control) did not change color, while the ones containing the substrate (positive control) turned blue
in the presence of commercially available free β-galactosidase, ruling out the possibility of alginate
contamination. The negative controls were subsequently used for background intensity subtraction
for LOD determination. Upon examination of radial cross-sections of positive controls (Figure 4b),
the presence of blue color (5,5′-dibromo-4,4′-dichloro-indigo) was an indicator of uniformly dimerized
X-Gal diffusion into the microcapsule.
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Figure 4. Negative (left) and positive (right) controls for the alginate bioassay-incubated controls in
commercial free β-galactosidase: (a) empty microcapsule; (b) microcapsule containing 2 mg/mL of
X-Gal. Scale bar represents 5 mm.
3.2. Assay Optimization and Confirmation Runs
Optimization results are summarized in Figure 5a–e and Table 3. The color changes in reaction
tubes labeled as a function of experimental run are presented in Supplementary Figure S1. Shown in
Figure 5 is a comparison of signal-to-noise ratios plotted by individual factor after 2 and 8 h assays.
There was a net quantifiable gain in dB as a result of extending the reaction time, although the trends
were translatable. Intensity monitoring continued for 10 h (not shown), but the assay became saturated
at the upper end of the categorical scale. The remainder of the analysis focused on a reaction time of
8 h. Based on color intensity (I) and signal-to-noise ratio ranks, BreastMilk Volume and Contamination
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Level (CFU/mL) were the top two factors, with Temperature, X-Gal Volume, and Lysing Time ranking
third, fourth, and fifth, respectively.
For the volume of breast milk, 150 µL of samples enabled the highest level of expression, as the S/N
increased with induction volume as illustrated in Figure 5a. The activation energy of X-Gal hydrolysis
and diffusion out of the assay increased with temperature. According to Figure 5e, there was a loss
of 2 dB when operating at the highest level of 45 ◦C. A two-fold mechanism for this decrease could
be proposed: (1) upon further visual examination of the samples (refer to Supplementary Figure S1),
this was attributed to the lack of the resolution of the blue color at the upper end of the categorical
scale; and (2) although no specific studies on beta-galactosidase activity were carried out on this
SCU-104 isolate, the optimum temperature for the enzyme from E. coli was reported to be at either
37 [33] or 50 ◦C [34]. Based on Figure 5e and the results obtained for the 2 h assay inspection time,
the values of signal-to-noise ratios were identical at 40 and 45 ◦C, and thus, the heat stability of the
enzyme at temperatures exceeding 40 ◦C may be in question for longer exposure times. With regards
to bacterial concentration, the higher the level of contamination, the higher the concentration of the
extracted enzyme and the theoretical X-Gal consumption. The optimum S/N was determined to be at
the highest volume of 100 µL. Theoretically, the higher the Lysing Time, the more the enzyme extracted
across combinations of Contamination Level. According to Figure 5b, there was an approximate loss
of 0.5 dB, which according to visual inspection may be have the same root cause as operating higher
temperatures or simply noise since the runs were not replicated.
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Figure 5. Signal-to-noise ratios plots for the Taguchi design variables: (a) Effect of Breastmilk Volume;
(b) Effect of Lysing Time; (c) Effect of X-Gal Volume; (d) Effect of Contamination Level; (e) Effect of
Temperature. Red and black lines correspond to incubation times f 2 h and 8 h, respectively.
The theoretical optimum levels of operation are presented in Table 3 as well as the pareto of effects
expressed in terms of rank. The gain at the optimal levels of variables was calculated to be 11.78 dB.
Before proceeding to the confirmation runs results of individual runs in terms of categorical
intensity (I) were re-examined for additional validation of theoretical analysis. Multiple optimal
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solutions as a combination of levels and variables were obtained as shown by the color change spectrum
displayed in Supplementary Figure S1, with the darkest blue intensities associated with runs G, L, M,
and N, characterized by respective gains of 9.20, 10.20, 10.22, and 11.12 dB. The variable settings for
run M (I = 8), which was chosen over run L (I = 8) for confirmation runs because of the higher rank of
induction volume in the signal-to-noise ratio and pareto of effects. Furthermore, run N (I = 8) was
not considered, because at 45 ◦C higher incubation times may affect the heat stability of the enzyme.
The conditions of run G (I = 7.5) were not selected because of the lower gain. Hence, run M was chosen
as the confirmation run.
Run M was triplicated with an average intensity score of 8 (I = 8), confirming the recommended
conditions. The lack of resolution of the categorical scale at the upper limit did not enable the
determination of a robust standard deviation.
Table 3. Optimized levels of operation for assay parameters for confirmation runs.
Variable Rank Optimal Rank Optimal Theoretical Confirmation
I (S/N) Recommended Run (M)
BreastMilk Volume 2 150 µL 1 150 µL 150 µL 150 µL
Lysing Time 5 20 min 5 20 min 20 min 10 min
X-Gal Volume 4 100 µL 4 100 µL 100 µL 100 µL
Contamination Level 1 3.16e7 2 3.16e7 1.00e7 1.00e7
Temperature 3 40 ◦C 3 40 ◦C 40 ◦C 40 ◦C
3.3. LOD Determination
In order to determine a lower LOD for the assay, optimal conditions determined for all other
variables were applied. A serial dilution range of 0–108 CFU/mL was subjected to a Lysing Time of
10 min and incubated at 40 ◦C with a single microcapsule containing 100 µL of X-Gal. Following
feature extraction using ImageJ and intensity normalization the results in Figure 6 were generated.
The results of hypothesis testing for significance between simulated levels of contamination at the
95% confidence interval (α = 0.05) are presented for average grayscale, and normalized intensities
followed by subsequent integration into the respective figures. Shown in Supplementary Figure S2
are the samples prior to feature extraction for assay development times of 2 and 8hr as well as the
grayscale and normalized intensity data.
As reflected by the norm of the calculated p-values in Figure 6a, there was no significant difference
in grayscale intensity between 0 and 10 CFU/mL, but there was a significant difference in average
intensity between 10 and 102 CFU/mL (p = 0.015). Statistical comparisons of normalized intensity values
shown in Figure 6b indicated statistically significant differences from 0 to 102 CFU/mL, positioning
the LOD at 10 CFU/mL. However, there was no statistical significance between 102 and 103 CFU/mL
(p = 0.2078), resulting in the poor linearity of the assay when the range was extended to 103 CFU/mL
(R2 = 0.8581). Combining the analyses from both intensity scales, a binary LOD of 102 CFU/mL and
above was determined.
3.4. Assay Development Material Cost
The cost range per assay at the optimal X-Gal concentration was calculated to be between $0.32
and $0.81. The complete assay included the gel capsule prototype ($0.0003) and X-Gal ($0.0047),
in conjunction with the B-PER lysing protocol ($0.32–$0.80).
4. Discussion
A unique key component of the assay was the entrapment of the X-Gal substrate in hydrogel
to conserve the normal (unreacted/pre-diffused) and hydrolyzed (dimerized product diffused back
into the microcapsule) conformations of X-Gal. In this case, alginate, a low-cost and well-researched
biomaterial, was chosen as the entrapment gel. The maximal color change was observed after 8 h
determined by multifactorial optimization.
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The composition of human milk is a dynamic variable ranging from 1 to 8 g/dL [13,35]. Sources of
variations include fluctuations between and within feed periods of lactation as well as differences between
mothers and populations. Since lactose and X-Gal competed as substrates for β-galactosidase, the relative
concentration of each could affect assay performance. For this reason, X-Gal concentration was included
as a variable in optimization experiments. The upper limit of the concentration range of the substrate of
0.2 g/dL (100 µL) used in the LOD experiments, an order of magnitude lower than the reported lactose




Figure 6. LOD determination under optimal assay conditions of run M and respective results of
significance testing between simulated contamination levels at a significance level of 5% (N = 3):
(a) (top) Grayscale intensity variation; (b) (bottom) Normalized intensity variation.
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While using a single batch of bacteria and a unique sample of breast milk for LOD determination,
the lack of linearity at the lower LOD can be attributed to the intensity normalization from the grayscale
in the absence of a lookup table (LUT). The above root cause contributed to the variation in grayscale
intensity at lower pathogen concentrations. At higher bacterial concentrations, these sources were
masked by the contrast in the grayscale generated by the stronger intensity of blue color as a result
of X-Gal dimerization. Combining future spectrophotometric absorbance measurements obtained
from the assay supernatant and grayscale intensities will enable the correlation of pixel intensity
to absorbance and hence the generation of a robust LUT. Furthermore, results will be collected at
additional bacterial concentration increments in the range of 0–103 CFU/mL.
Another hypothesis could be the nonuniform radial diffusion of the dimerized X-Gal into the
capsule, leading to an uneven distribution of intensity between the capsule and the solution. Although
this hypothesis can be refuted at higher concentrations as illustrated in Figure 4b, it is a factor to be
considered for lower detection limits.
Coupling spectrophotometric measurements to image analysis will shed light into whether a
change in immobilization morphology for X-Gal is necessary.
Based on a literature review, this proposed hydrogel-based assay has a number of competitive
advantages over technology currently in use for the detection of E. coli and/or other pathogens. In terms
of cost, the assay has the potential to become a low-cost point-of-use assay, with costs ranging from
$0.32 to $0.81, depending on the concentration of reagents used for the B-Per protein extraction method.
In a parallel study for the confirmation runs of the L16 design, the use of the Miller protocol [36]
brought the total cost of the assay down significantly to $0.046. Both the Miller protocol and the B-PER
protocol fall under the cost of $1.00 per assay [9]. While the Miller protocol would make the assay
cheaper than the current practice of bacterial culturing, it is not environmentally friendly due to the
use of chloroform. Special training for the careful handling of hazardous chloroform and access to
a hood are required. The price of a product utilizing B-PER for lysis is competitive with the cost of
current detection methods. The most economical immune-based test kit for water is the Watersafe®
Bacteria Test Kit, which detects E. coli, Pseudomonas, and many other forms of bacteria in 15 min at
less than $3 per test [37].
As far as pathogen detection in biofluids across paper-based, microfluidic and electrochemical
bioassays [38–42], the determined LOD of 102 CFU/mL and above is approximately two orders of
magnitude higher than the reported 0.093 CFU/mL for electrochemical immunoassays [43]. Furthermore,
amplification time and associated capital costs [34–37] are not required for the proposed hydrogel
assay. The closest general claims are for paper-based assays [38]. However, paper-based assays do not
reach the LOD achieved by alginate assays. The optimized assay development time of eight hours falls
within the range of 75 minutes [20] to 24 hours [33]. The capital costs of pasteurization to potentially
eliminate E. coli contamination are significantly high for human breast milk banks, ranging from $35 to
$81 to process approximately 100–200 ounces plus labor cost [11]. In essence, the assay outlined in
this technology could be used by workers with minimal training in the milk bank. Other technologies
require not only a large capital investment but specialized laboratory personnel to properly operate.
It has been reported that E. coli, Staphylococcus aureus, and group B 3-haemolytic streptococci are
potentially pathogenic organisms that are present in high counts in pooled human milk [44]. Practices
vary between milk banks concerning milk pool volume, post-pasteurization routine bacterial assessment,
bacteriological detection thresholds, and concentration standards for qualification [45,46]. However,
the large majority of North American milk banks assess their donated breast milk bacteriological
control based on the Human Milk Banking Association of North America (HMBANA) guideline [47],
and in many countries 104 CFU/mL is implemented as a cutoff number for E. coli and S. aureus [13].
In particular, in the province of Quebec, pre-pasteurization microbiological testing is performed for
total count screening for women entering the program. The milk is tested by inoculating 100 microliters
of a lot on nine blood agar plates. Plates used for the bacterial detection are incubated 48 h at 35 ◦C.
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Women having the presence of B. cereus, S. aureus, or enterobacterial at more than 10,000 CFU/mL or a
total count of more than 100,000 CFU/mL have their milk rejected [12].
Considering the reported binary LOD cutoff of 102 CFU/mL and above, this proposed
hydrogel-based assay is suited to meet requirements for screening breast milk or milk for pathogenic
organisms with a percentage of false positives to be determined.
5. Conclusions and Future Work
By simplifying the colorimetric assay design from a silicone-based paper platform to a bioactive
alginate microencapsulation platform, the specific aims of sensitivity (105 CFU/mL and lower), rapid
detection (two–eight hours), low cost, environmental friendliness associated with the research objectives
were achieved. Future efforts will encompass the following aspects: (1) examination of the effect of
varying lactose concentration on induction by using various batches of breast milk; (2) use of other
pathogenic bacterial strains commonly found as contaminants in breast milk; (3) optimization of
lysing/extraction steps for reducing assay development time and costs, as well as increasing sensitivity;
(4) development of a mobile app that can interpret and store detection results; (5) a twofold analysis
of quantitative results from categorical to continuous scale with regards to image processing and
automation with the aid of artificial intelligence; and (6) changes in assay morphology [48] guided by
spectrophotometric analysis.
Figure 7 is a proposed prototype for future efforts. To determine pathogen presence and quantify
the concentration, 150 µL the breast milk is deposited onto a two-dimensional (2D) membrane-based
sensor awaiting colorimetric detection. The paper-based alginate biosensor assay would be positioned
as a point of use triage diagnostic to indicate if further testing is warranted. The cutoff for the unsafe level
of contamination is shown for illustration purposes, since the level of virulence is pathogen-specific [12];
however, it satisfies the specification for milk.
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lysing solution. Subsequent confirmation runs were conducted using the conditions in run M. Figure S2: Raw 
data for the LOD determination after 8 hours of assay development and corresponding images prior to feature 
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of breastmilk was used to triplicate (M-A, M-B, M-C) the results under the conditions of run M using a 
Figure 7. Paper-based prototype kit composed f tral alginate slab and indicator scale. Note that
the cutoff of 104 CFU/mL between safe and u els is established for illustration urposes.
Supplem ntary Ma erials: The follow ng are availabl onli e at http://www.mdpi.com/1424-8220/20/4/1145/s1,
Figure S1: Samples correspo ding to the Taguchi design runs analyzed using the categorical color spectrum.
The labeling corresponds to the runs in Table 2. In each test tube a microcapsule was incubated with breast milk
and the lysing solution. Subsequent confirmation runs were conducted using the conditions in run M. Figure S2:
Raw data for the LOD determination after 8 hours of assay development and corresponding images prior to
feature extraction in Image J and intensity normalization (bottom row). A single batch of bacteria, using a single
batch of breastmilk was used to triplicate (M-A, M-B, M-C) the results under the conditions of run M using a
concentration ladder ranging from [0–108] CFU/mL. The images for the 2 hours of assay development are also
shown (top row) but have not been used for LOD determination.
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